{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:04:08Z","timestamp":1768993448691,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/wnf.0b013e3180d09969","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T07:01:05Z","timestamp":1206428465000},"page":"97-103","source":"Crossref","is-referenced-by-count":50,"title":["Topiramate in Essential Tremor"],"prefix":"10.1097","volume":"31","author":[{"given":"Gregory S.","family":"Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tarsy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJMcp010928","article-title":"Essential tremor.","volume":"345","author":"Louis","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00002018-200326070-00003","article-title":"Benefits and risks of pharmacological treatments for essential tremor.","volume":"26","author":"Lyons","year":"2003","journal-title":"Drug Saf"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1592\/phco.23.10.1105.32750","article-title":"Essential tremor: diagnosis and treatment.","volume":"23","author":"Chen","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1212\/WNL.55.10.1547","article-title":"Essential tremor frequency decreases with time.","volume":"55","author":"Elble","year":"2000","journal-title":"Neurology"},{"key":"R6-6-20210203","first-page":"908","article-title":"Topiramate as a novel treatment for essential tremorabstract.","volume":"14","author":"Connor","year":"1999","journal-title":"Mov Disord"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/1531-8249(200006)47:6<837::AID-ANA24>3.0.CO;2-2","article-title":"Topiramate and essential tremor.","volume":"47","author":"Galvez-Jimenez","year":"2000","journal-title":"Ann Neurol"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/WNL.59.1.132","article-title":"A double-blind placebo-controlled trial of topiramate treatment for essential tremor.","volume":"59","author":"Connor","year":"2002","journal-title":"Neurology"},{"issue":"suppl 3","key":"R10-6-20210203","first-page":"2","article-title":"Consensus statement of the Movement Disorders Society on tremor.","volume":"13","author":"Deuschl","year":"1998","journal-title":"Mov Disord"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s100720070069","article-title":"New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.","volume":"21","author":"Gunal","year":"2000","journal-title":"Neurol Sci"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1353-8020(03)00029-4","article-title":"A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor.","volume":"9","author":"Lee","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/mds.870130315","article-title":"Double-blind controlled trial of gabapentin in essential tremor.","volume":"13","author":"Pahwa","year":"1998","journal-title":"Mov Disord"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/archneur.56.4.475","article-title":"A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor.","volume":"56","author":"Gironell","year":"1999","journal-title":"Arch Neurol"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0","article-title":"Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.","volume":"15","author":"Ondo","year":"2000","journal-title":"Mov Disord"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1212\/WNL.43.5.1045","article-title":"Double-blind controlled study of methazolamide in the treatment of essential tremor.","volume":"43","author":"Busenbark","year":"1993","journal-title":"Neurology"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Gassmann-Mayer C, the EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures.","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1212\/01.WNL.0000048200.12663.BC","article-title":"A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy.","volume":"60","author":"Gilliam","year":"2003","journal-title":"Neurology"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Mattson RH, et al, for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Schmitt J, et al, for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial.","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch Neurol"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1345\/aph.10093","article-title":"Topiramate titration and tolerability.","volume":"35","author":"Biton","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/01.wnl.0000200779.03748.0f","article-title":"Topiramate in essential tremor: a double-blind, placebo-controlled trial.","volume":"66","author":"Ondo","year":"2006","journal-title":"Neurology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200803000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:51:32Z","timestamp":1618278692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200803000-00006"}},"subtitle":["Findings from Double-Blind, Placebo-Controlled, Crossover Trials"],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3180d09969","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}